Medindia

X

Sanofi Collaborates With German Biotech Company to Develop a New Class of Diabetes Drugs

by Reshma Anand on  August 7, 2015 at 4:54 PM Corporate News   - G J E 4
Sanofi collaborates with Evotec AG, a german biotech company to develop a new class of medicines to treat diabetes. Its focus is on developing a beta cell replacement therapy based on functional human beta cells derived from human stem cells.
 Sanofi Collaborates With German Biotech Company to Develop a New Class of Diabetes Drugs
Sanofi Collaborates With German Biotech Company to Develop a New Class of Diabetes Drugs
Advertisement

The collaboration will use human stem cells to develop drugs that bolster "Beta" cells, which release insulin and become impaired in people with diabetes. The drugs could reduce the need for diabetes patients to inject themselves with insulin, said Sanofi.

Advertisement
Sanofi could pay Evotec up to EUR300 million ($327.8 million) for hitting various drug development milestones, plus additional royalties on different drugs.

The collaboration will further enhance and complement Sanofi's extensive diabetes portfolio and will extend Evotec's metabolic disease and stem cell-based drug discovery programs.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All